liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin
Nw York.
Linköping University, Faculty of Health Sciences. Linköping University, Department of Medicine and Care, Internal Medicine. Östergötlands Läns Landsting, Centre for Medicine, Department of Endocrinology and Gastroenterology UHL.
Ullevål, Oslo.
Show others and affiliations
2007 (English)In: European Heart Journal, ISSN 0195-668X, Vol. 28, no 12, 1448-1453 p.Article in journal (Refereed) Published
Abstract [en]

Aims: The aim of the study was to evaluate the long-term cost-effectiveness of high-dose atorvastatin when compared with generic simvastatin for secondary prevention in Denmark, Finland, Norway, and Sweden based on the recently completed IDEAL trial. Methods and results: The IDEAL trial showed that high-dose treatment with atorvastatin was associated with fewer non-fatal myocardial infarctions (MI) or coronary heart disease death (RR 0.89, 95% CI 0.78-1.01) and major cardiovascular events by (RR 0.87, 95% CI 0.77-0.98) or any coronary event (RR 0.84, 95% CI 0.76-0.91) than simvastatin with no significant difference in the number of serious adverse events. Costs during the trial period was estimated based on the trial data and a Markov model was constructed where the risk of MIs and revascularization procedures and the long-term costs, quality of life, and mortality associated with these events was simulated. Costs were based on resource consumptions recorded in the trial multiplied with recent unit costs from each country. Both direct health care costs and indirect costs (costs from lost production due to work absence) were included. Intervention lasted for the duration of the trial (4.8 years) while health-effects and costs are predicted for the lifespan of the patient. The main outcome was quality adjusted life-years (QALY) gained. High-dose treatment was predicted to lead to a mean increase in survival of 0.049 years per patient and 0.033 QALYs gained. The cost to gain one QALY was predicted to 47 197€ (Denmark), 62 639€ (Finland), 35 210€ (Norway), and 43 667€ (Sweden), with cost-effectiveness ratio decreasing with higher risk. Conclusion: In the prevention of cardiovascular events among patients with a previous MI, high-dose atorvastatin appears to be a cost-effective strategy when compared with generic simvastatin 20-40 mg in Denmark, Norway, and Sweden. In Finland, it is cost-effective in high-risk patients. The key driver of the cost-effectiveness is the price-difference between 80 mg atorvastatin and generic simvastatin. © The European Society of Cardiology 2007. All rights reserved.

Place, publisher, year, edition, pages
2007. Vol. 28, no 12, 1448-1453 p.
National Category
Medical and Health Sciences
URN: urn:nbn:se:liu:diva-38241DOI: 10.1093/eurheartj/ehm020Local ID: 43099OAI: diva2:259090
Available from: 2009-10-10 Created: 2009-10-10 Last updated: 2011-01-11

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Olsson, Anders
By organisation
Faculty of Health SciencesInternal MedicineDepartment of Endocrinology and Gastroenterology UHL
In the same journal
European Heart Journal
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 31 hits
ReferencesLink to record
Permanent link

Direct link